MX2013005801A - Ensayos y biomarcadores para lrrk2. - Google Patents

Ensayos y biomarcadores para lrrk2.

Info

Publication number
MX2013005801A
MX2013005801A MX2013005801A MX2013005801A MX2013005801A MX 2013005801 A MX2013005801 A MX 2013005801A MX 2013005801 A MX2013005801 A MX 2013005801A MX 2013005801 A MX2013005801 A MX 2013005801A MX 2013005801 A MX2013005801 A MX 2013005801A
Authority
MX
Mexico
Prior art keywords
lrrk2
biomarkers
assays
screening
parkinson
Prior art date
Application number
MX2013005801A
Other languages
English (en)
Inventor
Daisy Bustos
Donald Kirkpatrick
Tracy Kleinheinz
John Moffat
Zejuan Sheng
Shuo Zhang
Haitao Zhu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2013005801A publication Critical patent/MX2013005801A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Biomarcadores para criba o detección de sujetos para enfermedad de Parkinson y proporcionar herramientas para diagnóstico complementarias para terapias que utilizan moduladores LRRK2, y ensayos para cribar o detectar compuestos y composiciones para modular actividad LRRK2.
MX2013005801A 2010-11-30 2011-11-29 Ensayos y biomarcadores para lrrk2. MX2013005801A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41820810P 2010-11-30 2010-11-30
PCT/US2011/062468 WO2012075046A1 (en) 2010-11-30 2011-11-29 Assays and biomarkers for lrrk2

Publications (1)

Publication Number Publication Date
MX2013005801A true MX2013005801A (es) 2013-07-17

Family

ID=45217723

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005801A MX2013005801A (es) 2010-11-30 2011-11-29 Ensayos y biomarcadores para lrrk2.

Country Status (9)

Country Link
EP (1) EP2646819A1 (es)
JP (1) JP2014504362A (es)
KR (1) KR20130121903A (es)
CN (1) CN103348243A (es)
BR (1) BR112013013457A2 (es)
CA (1) CA2818428A1 (es)
MX (1) MX2013005801A (es)
RU (1) RU2013129818A (es)
WO (1) WO2012075046A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6189948B2 (ja) 2012-06-29 2017-08-30 ファイザー・インク ＬＲＲＫ２阻害薬としての新規な４−（置換アミノ）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism
US9582909B2 (en) * 2012-11-15 2017-02-28 Shimadzu Corporation Chromatograph mass spectrometry data processing device
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
CN105331721A (zh) * 2015-11-27 2016-02-17 首都医科大学宣武医院 检测pd致病基因突变的方法，及其引物、试剂盒
RS62868B1 (sr) 2016-06-16 2022-02-28 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoli kao inhibitori lrrk2 za upotrebu u lečenju neurodegenerativnih poremećaja
MX2020004666A (es) 2017-11-17 2022-01-26 Cellix Bio Private Ltd Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0713738A2 (pt) 2006-06-20 2014-06-24 Novartis Ag Biomarcadores para a progressão de doença alzheimer
WO2008091799A2 (en) * 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
GB0706709D0 (en) * 2007-04-05 2007-05-16 Medical Res Council Methods
US20100175140A1 (en) * 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies
WO2010129053A2 (en) * 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
US8367349B2 (en) * 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2

Also Published As

Publication number Publication date
EP2646819A1 (en) 2013-10-09
WO2012075046A1 (en) 2012-06-07
KR20130121903A (ko) 2013-11-06
CA2818428A1 (en) 2012-06-07
CN103348243A (zh) 2013-10-09
RU2013129818A (ru) 2015-01-10
WO2012075046A9 (en) 2012-09-13
JP2014504362A (ja) 2014-02-20
BR112013013457A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
MX2013005801A (es) Ensayos y biomarcadores para lrrk2.
GB201014805D0 (en) Microfluidics based assay device
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2014042433A3 (en) Compounds and compositions for modulating adenosine a3 receptor activity
AU2016204248A1 (en) Boron-Containing Molecules
NZ612380A (en) Modulators of toll-like receptors
WO2010135717A3 (en) Complement assays and uses thereof
PH12014501108A1 (en) Anti-il-36r antibodies
MY161170A (en) Pyrimidine cyclohexyl glucocorticoid receptor modulators
MA34091B1 (fr) Anticorps anti-cd40
WO2014028461A3 (en) Treatment and diagnosis of melanoma
WO2010049144A3 (en) Ligands for modulation of orphan receptor-gamma (nr1f3 ) activity
WO2014099979A3 (en) Methods and compositions for identifying global microsatellite instability and for characterizing informative microsatellite loci
MX2020001160A (es) Anticuerpos y ensayos para la deteccion del receptor 1 de folato.
WO2011095623A3 (en) miRNA IN THE DIAGNOSIS OF OVARIAN CANCER
MX2015005448A (es) Metodos de terapia y diagnostico relacionados con lisil oxidasa-tipo 2 (loxl2).
MX2013005015A (es) Anticuerpos anti-il-23.
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
EP3736022A3 (en) Treatment and diagnosis of colon cancer
MX2012011829A (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
WO2011083483A3 (en) Method for treatment of inflammatory disease and disorder
MX2014006187A (es) Composiciones y metodos para el analisis de cancer de prostata.
WO2010141833A3 (en) Vital fluorochrome conjugates and methods of use
WO2011106785A3 (en) Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF

Legal Events

Date Code Title Description
FA Abandonment or withdrawal